Anuh Pharma has acquired a manufacturing facility in Tarapur, Maharashtra, from Vanquest Pharma for Rs 72.90 crore. The deal, involving land, building, and machinery, is set to boost the company’s API production capacity by 525 MTPA. This cash-based acquisition is an arm's length transaction.
Anuh Pharma Expands Production Footprint with Rs 72.9 Crore Acquisition
Anuh Pharma has finalized an Asset Transfer Agreement for Rs 72.90 crore.
The acquisition adds a 525 MTPA production capacity to the company's portfolio.
Reader Takeaway: Capacity expansion via strategic asset purchase boosts manufacturing growth while maintaining arm's length governance standards.
What just happened
Anuh Pharma has acquired a manufacturing facility located at F-10, M.I.D.C., Tarapur, Boisar, Palghar, Maharashtra. The deal encompasses the land, building, and all associated plant and machinery previously held by Vanquest Pharma Private Limited. The transaction is a cash-based deal and the company has explicitly stated that it does not involve any related parties.
Why this matters
This expansion is a direct move to scale the company’s manufacturing capabilities for Active Pharmaceutical Ingredients (APIs) and intermediates. By adding 525 MTPA of capacity, Anuh Pharma is positioning itself to handle larger order volumes and strengthen its competitive standing in the pharmaceutical supply chain.
Governance and Deal Structure
Anuh Pharma has clarified that the transaction is conducted at arm's length. No board representation will change as a result of this acquisition, and no new shares will be issued, ensuring no dilution for existing shareholders. The deal is entirely funded through cash, indicating the company is utilizing its liquidity to drive physical infrastructure growth.
What to track next
Investors should monitor the integration timeline for the new Tarapur unit and its subsequent contribution to the company’s quarterly revenue and production output figures in future earnings reports.